All In Biotech

Drug Trial Radar · NCT05194982

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

570

Planned (sponsor's estimate)

Start

Nov 29, 2021

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.
First posted
Jan 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be evaluated.

Conditions

  • Locally Advanced or Metastatic Solid Tumor

Interventions

  • BL-B01D1Drug

    Administration by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
  2. Phase Ia: Maximum tolerated dose (MTD)Time frame: Up to 21 days after the first dose
  3. Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to 21 days after the first dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Shanghai Oriental Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.